VistaGen Therapeutics, Inc. Stock

$2.38

0.00% yesterday

Nasdaq, Jul 14, 10:00 pm CET

ISIN

US92840H2022

Symbol

VTGN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

VistaGen Therapeutics, Inc. Stock price

$2.38

-13.81 85.30% 5Y

Nasdaq, Closing price Mon, Jul 14 2025

+0.00 0.00%

ISIN

US92840H2022

Symbol

VTGN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$69.4m

Enterprise Value

$-11.1m

Net debt

positive

Cash

$80.5m

Shares outstanding

29.0m

Valuation (TTM | estimate)

P/E

- | negative

P/S

- | 115.3

EV/Sales

- | negative

EV/FCF

0.3

P/B

1.0

Financial Health

Equity Ratio

83.5%

Return on Equity

-73.1%

ROCE

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

- | $601.8k

EBITDA

- | -

EBIT

- | $-76.1m

Net Income

- | $-50.3m

Free Cash Flow

$-42.3m

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

VistaGen Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a VistaGen Therapeutics, Inc. forecast:

9x Buy

90%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a VistaGen Therapeutics, Inc. forecast:

Buy

90%

Hold

10%

Analyst Estimates with Stock Price Targets

Financial data from VistaGen Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	0.70 0.70	33% 33% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	17 17	30% 30% 2,419%
- Research and Development Expense	37 37	67% 67% 5,229%
EBITDA	-52 -52	55% 55% -7,477%
- Depreciation and Amortization	0.50 0.50	317% 317% 71%
EBIT (Operating Income) EBIT	-53 -53	56% 56% -7,548%
Net Profit	-47 -47	47% 47% -6,757%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

VistaGen Therapeutics, Inc. Stock News

Neutral

Business Wire

●

19 days ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead the evalu...

Neutral

Seeking Alpha

●

27 days ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2025 Earnings Conference Call June 17, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Mark Adrian McPartland - Senior Vice President of Investor Relations Shawn K. Singh - President, CEO & Director Conference Call Participants Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Lin Tsa...

Neutral

Business Wire

●

27 days ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corporate update. “This was a defining ...

More VistaGen Therapeutics, Inc. News

Company Profile

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Head office	United States
CEO	Shawn Singh
Employees	48
Founded	1998
Website	www.vistagen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now